27 Aug 2015 Adocia and Lilly initiate new Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Icon check
21 Jul 2015 Adocia presents financial results for the first half of 2015 highlighting strong growth Icon check
10 Jul 2015 Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo
26 Jun 2015 Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Icon check
15 Jun 2015 Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices Icon check
05 Jun 2015 “Ultra-Rapid BioChaperone® Insulin Lispro (BC LIS): Linear Dose-Response and Faster Absorption than Insulin Lispro (LIS)” (Poster 979), presented by Dr. Grit Anderson, 75th Scientific Sessions of the American Diabetes Association, 5-9 June 2015, Boston, MA (USA)
28 May 2015 Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015 Icon check
26 May 2015 Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA) Icon check
04 May 2015 Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014 Icon check
29 Apr 2015 Adocia is now integrated into the EnterNext Tech 40 Index Icon check
20 Apr 2015 Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon Icon check
14 Apr 2015 Adocia announces first quarter 2015 results Icon check
16 Mar 2015 Adocia will present its 2014 annual results and its perspectives of growth during a conference call Icon check
10 Mar 2015 Adocia reports a strengthened cash position and intensifies clinical development Icon check
05 Mar 2015 Adocia opens a subsidiary in the USA and is pleased to appoint Simon Bruce, MD and Stephen Daly Icon check
17 Feb 2015 ADOCIA: annual revenue and net cash position for 2014 Icon check
10 Feb 2015 Adocia: modification of the means allocated to the liquidity agreement Icon check
05 Feb 2015 Adocia reports positive results from phase IIa clinical study of fast-acting human insulin, HinsBet Icon check
20 Jan 2015 Adocia initiates a clinical study on the post-meal effect of ultra-rapid BioChaperone Lispro insulin formulation Icon check
09 Jan 2015 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Icon check
29 Dec 2014 ADOCIA announces its financial calendar for 2015 Icon check
22 Dec 2014 ADOCIA: shareholder newsletter and invitation to two conference calls today and tomorrow Icon check
19 Dec 2014 Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology Icon check
16 Oct 2014 ADOCIA Announces Third-quarter Financial 2014 Results Icon check
30 Sep 2014 ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry Icon check
09 Sep 2014 Adocia Reports Positive Preliminary Results from Dose Response Clinical Study of Ultra-fast acting BioChaperone® Lispro U100 in Patients with Type 1 Diabetes Icon check
25 Aug 2014 Adocia Launches Phase III Clinical Study in India Of Treatment for Diabetic Foot Ulcer Icon check
24 Jul 2014 Adocia Reports Operational and Financial Results for the First Half of 2014 Icon check
10 Jul 2014 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Icon check
09 Jul 2014 Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes Icon check
24 Jun 2014 ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only)
16 Jun 2014 ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only)
14 Jun 2014 Résiliation du contrat de liquidité avec DSF Markets Icon check
13 Jun 2014 “Pharmacokinetic (PK) and Pharmacodynamic (PD) Characteristics of BioChaperone Combo (BC Combo), the First Fixed Combination of Glargine and Lispro, in Type 1 Diabetes”, (Poster 83-LB), presented by Dr. Ulrike Hövelmann, 74th Scientific Sessions American Diabetes Association 13-17 June 2014, San Francisco, CA, (USA)
13 Jun 2014 “The Ultra-Rapid BioChaperone® Insulin Lispro shows a Faster Onset of Action and Stronger Early Metabolic Effect than Native Insulin Lispro” (Poster 78-LB), presented by Dr. Grit Anderson, 74th Scientific Sessions of the American Diabetes Association, 13-17 June 2014, San Francisco, CA (USA)
10 Jun 2014 Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300 Icon check
04 Jun 2014 Adocia to Present Successful Clinical Results for BioChaperone® Lispro and BioChaperone® Combo at the American Diabetes Association 74th Scientific Sessions on June 15th 2014
27 May 2014 Adocia initiates ADR program in the United States Icon check
20 May 2014 Adocia: PR BC Lispro Initiation of phase 2a Icon check
19 May 2014 Adocia Press Release Liquidity Agreement with Kepler Icon check
06 May 2014 Termination of Liquidity Agreement with DSF Markets Icon check
10 Apr 2014 Adocia: Ultra Fast Lispro Clinical Results Icon check
10 Apr 2014 Adocia: Revenue Q1 2014 Icon check
26 Mar 2014 Gerard Soula Interview – La bourse et la vie (Transcript)
20 Mar 2014 Adocia: Annual results 2013 Icon check
17 Mar 2014 Adocia: confirmation of positive clinical results Combo Icon check
26 Feb 2014 Positive Clinical Results for Combo Icon check
10 Feb 2014 Adocia: Annual revenue of EUR 5.6 M in 2013 Icon check
29 Jan 2014 2014 Financial Calendar
20 Jan 2014 Half year report on Adocia’s liquidity agreement at December 2013 Icon check
Join our mailing list. Subscribe